Symbols / PYPD $4.71 +3.74% PolyPid Ltd.

Healthcare • Biotechnology • Israel • NCM
PYPD Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Fundamentals
Scroll to Statements
Market Cap 89.88M Enterprise Value 79.75M Income -34.17M Sales — Book/sh 0.60 Cash/sh 0.68
Dividend Yield — Payout 0.00% Employees 69 IPO — P/E — Forward P/E -5.09
PEG — P/S — P/B 7.81 P/C — EV/EBITDA -2.53 EV/Sales —
Quick Ratio 1.75 Current Ratio 1.97 Debt/Eq 25.48 LT Debt/Eq — EPS (ttm) -2.09 EPS next Y -0.93
EPS Growth — Revenue Growth — Earnings 2026-05-13 ROA -86.71% ROE -3.66% ROIC —
Gross Margin 0.00% Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 19.08M Shs Float 11.53M Short Float 0.32%
Short Ratio 0.81 Short Interest — 52W High 5.12 52W Low 2.44 Beta 1.46 Avg Volume 53.17K
Volume 39.81K Target Price $12.25 Recom Strong_buy Prev Close $4.54 Price $4.71 Change 3.74%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$12.25
Mean price target
2. Current target
$4.71
Latest analyst target
3. DCF / Fair value
$-14.90
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.71
Low
$9.00
High
$14.00
Mean
$12.25

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-11 reit HC Wainwright & Co. Buy → Buy $13
2025-11-13 main Roth Capital Buy → Buy $9
2025-08-14 main Craig-Hallum Buy → Buy $13
2025-08-13 reit HC Wainwright & Co. Buy → Buy $13
2025-06-18 main Roth Capital Buy → Buy $9
2025-06-17 main JMP Securities Market Outperform → Market Outperform $14
2025-06-09 main HC Wainwright & Co. Buy → Buy $13
2025-06-05 init Roth Capital — → Buy $9
2025-04-14 reit HC Wainwright & Co. Buy → Buy $11
2024-12-26 main HC Wainwright & Co. Buy → Buy $11
2024-12-16 reit HC Wainwright & Co. Buy → Buy $14
2024-11-04 init Craig-Hallum — → Buy $10
2024-10-02 reit HC Wainwright & Co. Buy → Buy $14
2024-08-15 reit HC Wainwright & Co. Buy → Buy $14
2024-06-18 reit HC Wainwright & Co. Buy → Buy $14
2024-05-09 reit HC Wainwright & Co. Buy → Buy $14
2024-05-01 reit HC Wainwright & Co. Buy → Buy $14
2023-10-23 main Barclays Equal-Weight → Equal-Weight $10
2023-10-12 init HC Wainwright & Co. — → Buy $16
2022-09-07 down Barclays Overweight → Equal-Weight $3
News
RSS: Latest PYPD news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
32.97
+17.62%
28.03
+22.57%
22.87
-41.20%
38.89
Research And Development
23.81
+4.37%
22.81
+41.26%
16.15
-42.31%
27.99
Selling General And Administration
9.16
+75.55%
5.22
-22.34%
6.72
-38.35%
10.90
Selling And Marketing Expense
1.98
+109.21%
0.94
-20.99%
1.20
-58.59%
2.89
General And Administrative Expense
7.18
+68.10%
4.27
-22.63%
5.52
-31.05%
8.01
Other Gand A
7.18
+68.10%
4.27
-22.63%
5.52
-31.05%
8.01
Total Expenses
32.97
+17.62%
28.03
+22.57%
22.87
-41.20%
38.89
Operating Income
-32.97
-17.62%
-28.03
-22.57%
-22.87
+41.20%
-38.89
Total Operating Income As Reported
-32.97
-17.62%
-28.03
-22.57%
-22.87
+41.20%
-38.89
EBITDA
-31.83
-23.15%
-25.85
-26.98%
-20.36
+45.23%
-37.17
Normalized EBITDA
-30.99
-19.39%
-25.96
-26.09%
-20.59
+44.60%
-37.17
Reconciled Depreciation
1.46
-10.11%
1.62
-10.98%
1.82
+5.87%
1.72
EBIT
-33.29
-21.19%
-27.47
-23.86%
-22.18
+42.97%
-38.89
Total Unusual Items
-0.84
-841.59%
0.11
-51.71%
0.23
-56.02%
0.53
Total Unusual Items Excluding Goodwill
-0.84
-841.59%
0.11
-51.71%
0.23
-56.02%
0.53
Special Income Charges
-0.51
0.00
0.00
—
Other Special Charges
0.51
—
—
—
Net Income
-34.17
-17.73%
-29.02
-21.61%
-23.86
+39.67%
-39.56
Pretax Income
-34.16
-17.89%
-28.98
-21.79%
-23.80
+39.65%
-39.43
Net Non Operating Interest Income Expense
-0.36
+66.26%
-1.06
+8.51%
-1.16
-115.37%
-0.54
Interest Expense Non Operating
0.87
-42.12%
1.51
-6.67%
1.62
+199.63%
0.54
Net Interest Income
-0.36
+66.26%
-1.06
+8.51%
-1.16
-115.37%
-0.54
Interest Expense
0.87
-42.12%
1.51
-6.67%
1.62
+199.63%
0.54
Interest Income Non Operating
0.52
+16.97%
0.44
-19.34%
0.55
+105.24%
0.27
Interest Income
0.52
+16.97%
0.44
-19.34%
0.55
+105.24%
0.27
Other Income Expense
-0.84
-841.59%
0.11
-51.71%
0.23
-56.02%
0.53
Gain On Sale Of Security
-0.33
-388.50%
0.11
-51.71%
0.23
-56.02%
0.53
Tax Provision
0.01
-88.10%
0.04
-39.13%
0.07
-46.51%
0.13
Tax Rate For Calcs
0.00
-100.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
0.03
-51.71%
0.05
0.00
Net Income Including Noncontrolling Interests
-34.17
-17.73%
-29.02
-21.61%
-23.86
+39.67%
-39.56
Net Income From Continuing Operation Net Minority Interest
-34.17
-17.73%
-29.02
-21.61%
-23.86
+39.67%
-39.56
Net Income From Continuing And Discontinued Operation
-34.17
-17.73%
-29.02
-21.61%
-23.86
+39.67%
-39.56
Net Income Continuous Operations
-34.17
-17.73%
-29.02
-21.61%
-23.86
+39.67%
-39.56
Normalized Income
-33.33
-14.50%
-29.11
-21.06%
-24.05
+39.21%
-39.56
Net Income Common Stockholders
-34.17
-17.73%
-29.02
-21.61%
-23.86
+39.67%
-39.56
Otherunder Preferred Stock Dividend
—
—
—
0.00
Diluted EPS
—
-4.91
+71.10%
-16.99
+72.10%
-60.90
Basic EPS
—
-4.91
+71.10%
-16.99
+72.10%
-60.90
Basic Average Shares
—
5.91
+321.04%
1.40
+116.87%
0.65
Diluted Average Shares
—
5.91
+316.02%
1.42
+119.49%
0.65
Diluted NI Availto Com Stockholders
-34.17
-17.73%
-29.02
-21.61%
-23.86
+39.67%
-39.56
Total Other Finance Cost
0.00
+150.00%
-0.00
-104.30%
0.09
-70.57%
0.32
Line Item Trend 2023-12-31
Total Assets
15.37
Current Assets
6.07
Cash Cash Equivalents And Short Term Investments
5.31
Cash And Cash Equivalents
5.31
Other Short Term Investments
0.00
Receivables
—
Other Receivables
—
Inventory
—
Prepaid Assets
0.35
Restricted Cash
0.30
Other Current Assets
0.11
Total Non Current Assets
9.30
Net PPE
9.22
Gross PPE
17.02
Accumulated Depreciation
-7.80
Properties
0.00
Machinery Furniture Equipment
0.79
Other Properties
9.72
Leases
6.50
Non Current Prepaid Assets
—
Other Non Current Assets
0.09
Total Liabilities Net Minority Interest
17.47
Current Liabilities
7.29
Payables And Accrued Expenses
2.73
Payables
0.77
Accounts Payable
0.77
Other Payable
—
Current Accrued Expenses
1.95
Current Debt And Capital Lease Obligation
4.54
Current Debt
4.00
Other Current Borrowings
4.00
Current Capital Lease Obligation
0.54
Current Deferred Liabilities
—
Current Deferred Revenue
—
Other Current Liabilities
0.02
Total Non Current Liabilities Net Minority Interest
10.18
Long Term Debt And Capital Lease Obligation
7.24
Long Term Debt
6.38
Long Term Capital Lease Obligation
0.86
Non Current Deferred Liabilities
2.55
Non Current Deferred Revenue
2.55
Other Non Current Liabilities
0.40
Stockholders Equity
-2.10
Common Stock Equity
-2.10
Capital Stock
0.00
Common Stock
0.00
Share Issued
1.65
Ordinary Shares Number
1.65
Treasury Shares Number
0.00
Additional Paid In Capital
236.21
Retained Earnings
-238.31
Total Equity Gross Minority Interest
-2.10
Total Capitalization
4.28
Working Capital
-1.22
Invested Capital
8.29
Total Debt
11.78
Net Debt
5.07
Capital Lease Obligations
1.40
Net Tangible Assets
-2.10
Tangible Book Value
-2.10
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-27.88
-26.94%
-21.96
-27.43%
-17.24
+49.77%
-34.32
Cash Flow From Continuing Operating Activities
-27.88
-26.94%
-21.96
-27.43%
-17.24
+49.77%
-34.32
Net Income From Continuing Operations
-34.17
-17.73%
-29.02
-21.61%
-23.86
+39.67%
-39.56
Depreciation Amortization Depletion
1.46
-10.11%
1.62
-10.98%
1.82
+5.87%
1.72
Depreciation
1.46
-10.11%
1.62
-10.98%
1.82
+5.87%
1.72
Depreciation And Amortization
1.46
-10.11%
1.62
-10.98%
1.82
+5.87%
1.72
Other Non Cash Items
-0.89
-228.12%
0.70
-59.64%
1.73
+497.58%
0.29
Stock Based Compensation
4.85
+71.88%
2.82
-16.72%
3.39
-21.27%
4.31
Operating Gains Losses
0.51
—
-0.20
—
Gain Loss On Investment Securities
—
—
-0.20
—
Change In Working Capital
0.36
-81.26%
1.92
+1841.82%
-0.11
+89.79%
-1.08
Change In Prepaid Assets
-0.23
+28.57%
-0.32
-149.14%
0.64
-45.91%
1.19
Change In Payables And Accrued Expense
0.35
-83.47%
2.13
+350.59%
-0.85
+81.16%
-4.51
Change In Accrued Expense
0.17
-65.11%
0.49
+202.49%
-0.48
+66.03%
-1.42
Change In Payable
0.18
-89.00%
1.64
+543.63%
-0.37
+88.08%
-3.10
Change In Account Payable
0.18
-89.00%
1.64
+543.63%
-0.37
+88.08%
-3.10
Change In Other Working Capital
—
—
—
2.55
Change In Other Current Assets
0.91
+10.07%
0.82
+38.95%
0.59
+124.39%
-2.43
Change In Other Current Liabilities
-0.68
+6.64%
-0.72
-46.36%
-0.49
-123.17%
2.13
Investing Cash Flow
-6.70
-1931.52%
-0.33
-108.68%
3.80
-77.05%
16.57
Cash Flow From Continuing Investing Activities
-6.70
-1931.52%
-0.33
-108.68%
3.80
-77.05%
16.57
Net PPE Purchase And Sale
-0.21
-176.32%
-0.08
+61.22%
-0.20
+88.91%
-1.77
Purchase Of PPE
-0.21
-176.32%
-0.08
+61.22%
-0.20
+88.91%
-1.77
Capital Expenditure
-0.21
-176.32%
-0.08
+61.22%
-0.20
+88.91%
-1.77
Net Investment Purchase And Sale
-6.49
-2456.69%
-0.25
-106.35%
4.00
-78.19%
18.34
Purchase Of Investment
-26.22
-22.77%
-21.35
-14.80%
-18.60
-165.71%
-7.00
Sale Of Investment
19.72
-6.53%
21.10
-6.64%
22.60
-10.82%
25.34
Financing Cash Flow
25.37
-21.74%
32.42
+224.94%
9.98
-39.27%
16.43
Cash Flow From Continuing Financing Activities
25.37
-21.74%
32.42
+224.94%
9.98
-39.27%
16.43
Net Issuance Payments Of Debt
-6.38
-91.93%
-3.32
-26.89%
-2.62
-123.15%
11.31
Issuance Of Debt
—
0.00
0.00
-100.00%
11.71
Repayment Of Debt
-6.38
-91.93%
-3.32
-26.89%
-2.62
-551.24%
-0.40
Long Term Debt Issuance
—
0.00
0.00
-100.00%
11.71
Long Term Debt Payments
-6.38
-91.93%
-3.32
-26.89%
-2.62
-551.24%
-0.40
Net Long Term Debt Issuance
-6.38
-91.93%
-3.32
-26.89%
-2.62
-123.15%
11.31
Net Common Stock Issuance
32.60
-9.09%
35.86
+182.16%
12.71
+153.64%
5.01
Proceeds From Stock Option Exercised
0.00
0.00
-100.00%
0.01
-91.67%
0.11
Net Other Financing Charges
-0.86
-587.20%
-0.12
+0.00%
-0.12
—
Changes In Cash
-9.21
-191.02%
10.12
+392.91%
-3.46
-163.01%
-1.31
Beginning Cash Position
15.81
+178.03%
5.69
-37.80%
9.14
-12.57%
10.46
End Cash Position
6.59
-58.28%
15.81
+178.03%
5.69
-37.80%
9.14
Free Cash Flow
-28.09
-27.45%
-22.04
-26.43%
-17.43
+51.69%
-36.08
Interest Paid Supplemental Data
0.56
-41.37%
0.95
-8.48%
1.04
+41.42%
0.73
Income Tax Paid Supplemental Data
0.01
+66.67%
0.00
-83.33%
0.02
+125.00%
0.01
Common Stock Issuance
32.60
-9.09%
35.86
+182.16%
12.71
+153.64%
5.01
Issuance Of Capital Stock
32.60
-9.09%
35.86
+182.16%
12.71
+153.64%
5.01
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category